Literature DB >> 12476323

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.

B Dean1, M McLeod, D Keriakous, J McKenzie, E Scarr.   

Abstract

To test the hypothesis that muscarinic receptors are involved in the pathology of schizophrenia, we measured muscarinic(1) (M1R) and muscarinic(4)(M4R) protein and mRNA as well as [(3)H]pirenzepine binding in Brodmann's areas (BA) 9 and 40 obtained postmortem from 20 schizophrenic and 20 age/sex-matched control subjects. There was a significant decrease in [(3)H]pirenzepine binding to BA 9 (mean +/- SEM: 151 +/- 15 vs 195 +/- 10 fmol mg(-1) ETE; P< 0.02), but not BA 40 (143 +/- 13 vs 166 +/- 11 fmol mg(-1) ETE), from subjects with schizophrenia. The level of M1R protein (0.11 +/- 0.007 vs 0.15 +/- 0.008 OD; P < 0.01), but not M4R protein, was decreased in BA9 from schizophrenic subjects with neither receptor protein being altered in BA 40. The level of M1R mRNA was decreased in BA 9 (30 +/- 7.0 vs 79 +/- 14 dpm x 10(3) mg(-1) ETE, P < 0.01) and BA 40 (28 +/- 5.9 vs 99 +/- 14, P < 0.01) with schizophrenia but M4R mRNA was only decreased in BA 40 (48 +/- 6.6 vs 89 +/- 9.9, P < 0.005). These data suggest that the M1R, at least in the dorsolateral prefrontal cortex, may have a role in the pathology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476323     DOI: 10.1038/sj.mp.4001199

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  68 in total

1.  Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Authors:  Jelveh Lameh; Krista McFarland; Jorgen Ohlsson; Fredrik Ek; Fabrice Piu; Ethan S Burstein; Ali Tabatabaei; Roger Olsson; Stefania Risso Bradley; Douglas W Bonhaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

Review 4.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

Review 5.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

6.  Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.

Authors:  Salma R I Ribeiz; Débora P Bassitt; Jony A Arrais; Renata Avila; David C Steffens; Cássio M C Bottino
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

7.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

Review 8.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

9.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

10.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.